{"title":"Racial disparities in non-small cell lung cancer survival outcomes: a systematic review and meta-analysis.","authors":"Chalothorn Wannaphut, Ben Ponvilawan, Chanakarn Kanitthamniyom, Pojsakorn Danpanichkul, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Phuuwadith Wattanachayakul, Sakditad Saowapa","doi":"10.1080/08998280.2025.2524792","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Previous studies have demonstrated disparities in survival outcomes between Black/African American, Asian, and White patients with non-small cell lung cancer (NSCLC). Some studies have suggested that non-White patients have poorer survival outcomes due to socioeconomic factors, while others have reported different findings. Therefore, we performed a comprehensive review and meta-analysis to evaluate the impact of racial disparity on NSCLC survival outcomes.</p><p><strong>Method: </strong>PubMed, Ovid MEDLINE, Embase, and Google Scholar were searched for articles published until September 2024. Eligible studies with aligned research objectives were included. Two reviewers independently extracted data. Methodological quality was assessed using the Newcastle-Ottawa Scale. The meta-analysis adhered to the PRISMA guidelines.</p><p><strong>Result: </strong>Fifteen studies with 763,314 patients met the eligibility criteria. Asian and Asian/Pacific Islander (API) patients had significantly better overall survival (OS) compared to White patients (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.79-0.94; <i>P</i> < 0.01 and HR, 0.80; 95% CI, 0.69-0.93; <i>P</i> < 0.01, respectively). In contrast, OS differences were not statistically significant between Black and White (HR, 1.00; 95% CI, 0.94-1.07; <i>P</i> < 0.01) or Hispanic and White patients (HR, 0.93; 95% CI, 0.87-1.00; <i>P</i> = 0.19). Further, the subgroup analyses did not demonstrate any significant difference in OS outcome in any stage when comparing Black to White patients (stage I HR, 1.11; 95% CI, 1.00-1.23; <i>P</i> < 0.01; stage II HR, 1.03; 95% CI, 0.96-1.10; <i>P</i> = 0.26; stage III HR, 1.04; 95% CI, 0.96-1.12; <i>P</i> < 0.01; and stage IV HR, 1.02; 95% CI, 0.97-1.07; <i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>Asian and API patients with NSCLC exhibited superior OS outcomes compared to White patients. In contrast, racial disparities in survival outcomes were statistically insignificant for Black and Hispanic patients. Additionally, staging disparities in OS were not observed between Black and White patients with NSCLC.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 5","pages":"722-731"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351699/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2025.2524792","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Previous studies have demonstrated disparities in survival outcomes between Black/African American, Asian, and White patients with non-small cell lung cancer (NSCLC). Some studies have suggested that non-White patients have poorer survival outcomes due to socioeconomic factors, while others have reported different findings. Therefore, we performed a comprehensive review and meta-analysis to evaluate the impact of racial disparity on NSCLC survival outcomes.
Method: PubMed, Ovid MEDLINE, Embase, and Google Scholar were searched for articles published until September 2024. Eligible studies with aligned research objectives were included. Two reviewers independently extracted data. Methodological quality was assessed using the Newcastle-Ottawa Scale. The meta-analysis adhered to the PRISMA guidelines.
Result: Fifteen studies with 763,314 patients met the eligibility criteria. Asian and Asian/Pacific Islander (API) patients had significantly better overall survival (OS) compared to White patients (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.79-0.94; P < 0.01 and HR, 0.80; 95% CI, 0.69-0.93; P < 0.01, respectively). In contrast, OS differences were not statistically significant between Black and White (HR, 1.00; 95% CI, 0.94-1.07; P < 0.01) or Hispanic and White patients (HR, 0.93; 95% CI, 0.87-1.00; P = 0.19). Further, the subgroup analyses did not demonstrate any significant difference in OS outcome in any stage when comparing Black to White patients (stage I HR, 1.11; 95% CI, 1.00-1.23; P < 0.01; stage II HR, 1.03; 95% CI, 0.96-1.10; P = 0.26; stage III HR, 1.04; 95% CI, 0.96-1.12; P < 0.01; and stage IV HR, 1.02; 95% CI, 0.97-1.07; P < 0.01).
Conclusion: Asian and API patients with NSCLC exhibited superior OS outcomes compared to White patients. In contrast, racial disparities in survival outcomes were statistically insignificant for Black and Hispanic patients. Additionally, staging disparities in OS were not observed between Black and White patients with NSCLC.
背景:先前的研究已经证明黑人/非裔美国人、亚洲人和白人非小细胞肺癌(NSCLC)患者的生存结局存在差异。一些研究表明,由于社会经济因素,非白人患者的生存结果较差,而其他研究则报告了不同的结果。因此,我们进行了一项全面的综述和荟萃分析,以评估种族差异对NSCLC生存结果的影响。方法:检索PubMed、Ovid MEDLINE、Embase、谷歌Scholar等数据库中2024年9月前发表的文章。纳入了符合研究目标的合格研究。两名审稿人独立提取数据。采用纽卡斯尔-渥太华量表评估方法学质量。meta分析遵循PRISMA指南。结果:15项研究共763314例患者符合入选标准。亚洲和亚洲/太平洋岛民(API)患者的总生存期(OS)明显优于白人患者(风险比[HR], 0.86; 95%可信区间[CI], 0.79-0.94; P P P P = 0.19)。此外,亚组分析未显示黑人和白人患者在任何阶段的OS结果有任何显著差异(I期HR, 1.11; 95% CI, 1.00-1.23; P = 0.26; III期HR, 1.04; 95% CI, 0.96-1.12; P P)结论:亚洲和API患者的NSCLC的OS结果优于白人患者。相比之下,黑人和西班牙裔患者生存结果的种族差异在统计上微不足道。此外,黑人和白人NSCLC患者的OS分期差异未见。